Welcome! Login | Register
 

Central MA Man Found Guilty of Murdering Ex. Wife’s Twin Sister—Spencer Resident Found Guilty in 2012 Death of…

Leominster Attorney Named to Serve on Supreme Judicial Court Nominating Commission—Leominster Attorney Named Part of Supreme Judicial Court…

25 Cities That Have Become More Single—25 Cities That Have Become More Single

Will Worcester Give Its Heart to Yet Another Hockey Team—The History of Hockey in Worcester

A History of Hockey in Worcester—A History of Hockey in Worcester

Celtics Host Paul Pierce, Doc Rivers & The LA Clippers Tonight—Celtics Host Paul Pierce, Doc Rivers & The…

Pro Hockey is Returning to Worcester in 2017—NEW: Pro Hockey is Returning to Worcester in…

10 Great Pets in Need of Loving Homes - Feb. 9—Calling all animal lovers! - 10 Great Pets…

FBI Files - The Patriarca Papers - Entry 27 (Rocky Marciano, John Chafee, and Joe Mollicone)—FBI Files - The Patriarca Papers - Entry…

Cheat Sheet 27, FBI Files: FBI Tips League About Patriots’ Betting, Chafee’s Impact on Patriarca—Cheat Sheet 27, FBI Files: FBI Tips League…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.